IL6 and rheumatoid arthritis: We sought parallels in effector phenotype between “IL-6 primed” effector CD4+ T cells, assessed in our in vitro model of prior IL-6 exposure, and ex vivo CD4+ T cells from drug-naïve early RA patients.